6541 — Tanvex Biopharma Income Statement
0.000.00%
Last trade - 00:00
- TWD10.99bn
- TWD11.69bn
- TWD61.41m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.3 | 5.41 | 22.4 | 61.4 |
Cost of Revenue | |||||
Gross Profit | 0 | 0.143 | 3.55 | -19.3 | 59.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2,328 | 2,100 | 1,605 | 1,628 | 2,171 |
Operating Profit | -2,328 | -2,100 | -1,599 | -1,606 | -2,109 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2,274 | -2,104 | -1,543 | -1,641 | -2,137 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2,274 | -2,104 | -1,543 | -1,641 | -2,137 |
Net Income Before Extraordinary Items | |||||
Net Income | -2,274 | -2,104 | -1,543 | -1,641 | -2,137 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -2,274 | -2,104 | -1,543 | -1,641 | -2,137 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -25.8 | -22.2 | -13.7 | -13.4 | -16.3 |
Dividends per Share |